富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301258 富士莱

已收盘 12-23 15:00:00

{"stockData":{"symbol":"301258","market":"SZ","secType":"STK","nameCN":"富士莱","latestPrice":32.97,"timestamp":1766473398000,"preClose":33.36,"halted":0,"volume":1202006,"delay":0,"changeRate":-0.0117,"floatShares":89065000,"shares":91670000,"eps":0.8287,"marketStatus":"已收盘","change":-0.39,"latestTime":"12-23 15:00:00","open":33.11,"high":33.36,"low":32.62,"amount":39532400,"amplitude":0.0222,"askPrice":32.99,"askSize":1,"bidPrice":32.97,"bidSize":13,"shortable":0,"etf":0,"ttmEps":0.8287,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":5,"adr":0,"adjPreClose":33.36,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":36.7,"lowLimit":30.02,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":91670000,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":39.785206,"roe":"3.83%","epsLYR":0.18,"committee":-0.09375,"marketValue":3022000000,"turnoverRate":0.0135,"status":1,"floatMarketCap":2936000000},"requestUrl":"/m/hq/s/301258","defaultTab":"news","newsList":[{"id":"2593432630","title":"股市必读：富士莱（301258）12月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2593432630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593432630?lang=zh_cn&edition=full","pubTime":"2025-12-23 02:21","pubTimestamp":1766427673,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，富士莱报收于33.36元，上涨4.09%，换手率2.72%，成交量2.43万手，成交额8052.04万元。董秘最新回复投资者： 尊敬的董秘，您好！今天是12月中旬最后一个交易日，敬请发布截至今天公司的股东户数信息。请问截止至2025年12月19日，公司股东人数总数是多少?截至2025年12月19日股东总户数为9,810户，感谢您对公司的关注！当日关注点来自交易信息汇总：12月22日主力资金净流入493.67万元，显示主力对个股呈积极介入态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300001318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2593210298","title":"富士莱：截至2025年12月19日股东总户数为9,810户","url":"https://stock-news.laohu8.com/highlight/detail?id=2593210298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593210298?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:42","pubTimestamp":1766389330,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，截至2025年12月20日公司的股东总数是多少？谢谢富士莱回复：尊敬的投资者，您好！截至2025年12月19日股东总户数为9,810户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200013001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2590982755","title":"富士莱：截至2025年12月10日股东总户数为9,811户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590982755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590982755?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:51","pubTimestamp":1765439476,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至12月10今天收盘公司的股东户数信息。谢谢！致礼！富士莱回复：尊敬的投资者，您好！截至2025年12月10日股东总户数为9,811户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100020023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2590342507","title":"富士莱（301258）披露获得硫辛酸片药品注册证书，12月9日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590342507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590342507?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:28","pubTimestamp":1765290523,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，富士莱报收于32.62元，较前一交易日下跌0.67%，最新总市值为29.9亿元。该股当日开盘32.86元，最高32.99元，最低32.5元，成交额达2168.33万元，换手率为0.74%。公司近日发布公告称，苏州富士莱医药股份有限公司近日收到国家药品监督管理局签发的硫辛酸片药品注册证书，药品名称为硫辛酸片，剂型为片剂，规格为0.2g和0.6g，注册分类为化学药品3类，上市许可持有人为公司自身。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900041266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2590130173","title":"富士莱(301258.SZ)获硫辛酸片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590130173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590130173?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:55","pubTimestamp":1765266950,"startTime":"0","endTime":"0","summary":"智通财经APP讯，富士莱(301258.SZ)公告，公司近日收到国家药品监督管理局签发的关于硫辛酸片的《药品注册证书》。硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"富士莱(301258.SZ)获硫辛酸片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2588742709","title":"富士莱：截至2025年11月28日股东总户数为10,214户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588742709","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588742709?lang=zh_cn&edition=full","pubTime":"2025-12-01 15:54","pubTimestamp":1764575649,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！今天是11月最后一个交易日，敬请发布截至11月末公司股东户数信息。        感谢您每期都花费时间和精力回复提问。谢谢！富士莱回复：尊敬的投资者，您好！截至2025年11月28日股东总户数为10,214户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100013382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2586428645","title":"富士莱：瑞玞生物主营医美产品研发销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586428645?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:31","pubTimestamp":1764059472,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，公司全资子公司贝格致远投资的神济昌华以及瑞玞生物分别是做什么的，两家市场前景如何。富士莱回复：尊敬的投资者，您好！公司子公司苏州贝格致远投资管理有限公司已收回对神济昌华（北京）生物科技有限公司的投资；瑞玞生物主要业务为医疗器械和化妆品系列医美产品的研发、生产和销售。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500021730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2586286244","title":"富士莱：山东项目投产将提升核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2586286244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586286244?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:31","pubTimestamp":1764059471,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司山东项目建设完成全部投产后预计可以为公司带来多少的经济效应。富士莱回复：尊敬的投资者，您好！“富士莱（山东）特色原料药及中间体CMO/CDMO建设项目”投产后将有助于提升公司在特色原料药及中间体领域的核心竞争力，为公司的可持续发展注入新动能。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500021731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2586627428","title":"富士莱：阿帕替尼原料药获GMP符合性认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2586627428","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586627428?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:30","pubTimestamp":1764059458,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司阿帕替尼原料药项目进展如何。富士莱回复：尊敬的投资者，您好！截至目前，公司已收到江苏省药品监督管理局的药品GMP符合性检查结果告知书，获悉公司原料药甲磺酸阿帕替尼符合药品GMP，为后续的商业化奠定坚实的基础。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500021700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2585873118","title":"富士莱：截至2025年11月20日股东总户数为10,436户","url":"https://stock-news.laohu8.com/highlight/detail?id=2585873118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585873118?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:12","pubTimestamp":1763712729,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月21日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至今天11月20日公司的股东户数信息。谢谢！富士莱回复：尊敬的投资者，您好！截至2025年11月20日股东总户数为10,436户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100019514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2584329158","title":"富士莱（301258）披露关于回购股份实施完成暨股份变动的公告，11月20日股价下跌1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584329158","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584329158?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:41","pubTimestamp":1763649681,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于回购股份实施完成暨股份变动的公告》，公告称，苏州富士莱医药股份有限公司于2025年10月13日召开董事会，审议通过使用自有资金回购公司股份的方案，回购资金总额不低于2,000万元且不超过4,000万元，回购价格不超过40.00元/股，用于未来股权激励或员工持股计划。回购股份将用于员工持股计划或股权激励，若三年内未使用将予以注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2582755348","title":"富士莱：截至2025年11月10日股东总户数为10,653户","url":"https://stock-news.laohu8.com/highlight/detail?id=2582755348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582755348?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:36","pubTimestamp":1762918571,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月11日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，截止到2025年11月10日股东人数是多少？富士莱回复：尊敬的投资者，您好！截至2025年11月10日股东总户数为10,653户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200014537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2582767368","title":"富士莱年产289吨特色原料药扩建项目延期","url":"https://stock-news.laohu8.com/highlight/detail?id=2582767368","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582767368?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:01","pubTimestamp":1762776060,"startTime":"0","endTime":"0","summary":"富士莱表示，此次项目延期主要是由于在项目审查阶段需要对原厂房设施及生产线与现行相关标准规范辨识，对不符合的内容提出改造方案，并向监管部门和各专业专家咨询论证，导致项目审查周期延长。　　同时，富士莱公告称，公司拟将“富士莱（山东）特色原料药及中间体CMO/CDMO建设项目”的投资总额由25000万元调整至31000万元，新增投资金额使用超募资金投入，同时对该项目内部投资结构进行调整。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-10/doc-infwxnsv2913345.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-10/doc-infwxnsv2913345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2580627632","title":"富士莱：截至2025年10月31日股东总户数为10,911户","url":"https://stock-news.laohu8.com/highlight/detail?id=2580627632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580627632?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:33","pubTimestamp":1762158789,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，您好！敬请发布截至10月底公司股东户数信息。谢谢！致礼！富士莱回复：尊敬的投资者，您好！截至2025年10月31日股东总户数为10,911户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300021647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2579849346","title":"富士莱：累计回购公司股份920000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579849346","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579849346?lang=zh_cn&edition=full","pubTime":"2025-10-31 22:09","pubTimestamp":1761919740,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月31日晚间，富士莱发布公告称，截至2025年10月31日，公司通过股票回购专用证券账户以集中竞价交易方式累计回购公司股份数量为920，000股，占公司目前总股本的1.0036%。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvvcyf8441540.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvvcyf8441540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2578525718","title":"富士莱（301258）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2578525718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578525718?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:11","pubTimestamp":1761343896,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期富士莱发布2025年三季报。根据财报显示，富士莱营收净利润同比双双增长。截至本报告期末，公司营业总收入3.23亿元，同比上升3.23%，归母净利润7339.66万元，同比上升430.16%。按单季度数据看，第三季度营业总收入9867.49万元，同比上升2.95%，第三季度归母净利润3032.0万元，同比上升113.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258"],"gpt_icon":0},{"id":"2577583954","title":"富士莱（301258）披露2025年三季度报告，10月23日股价上涨1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577583954","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577583954?lang=zh_cn&edition=full","pubTime":"2025-10-23 22:20","pubTimestamp":1761229228,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘，富士莱报收于35.94元，较前一交易日上涨1.9%，最新总市值为32.95亿元。该股当日开盘35.19元，最高35.98元，最低34.99元，成交额达7244.21万元，换手率为2.29%。近日，富士莱发布2025年第三季度报告。公告显示，公司2025年前三季度实现营业收入322,584,658.78元，同比增长3.23%；归属于上市公司股东的净利润为73,396,632.64元，同比增长430.16%；基本每股收益0.8099元，同比增长436.36%。股东信息方面，截至报告期末，公司普通股股东总数为11,070户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300037798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301258"],"gpt_icon":0},{"id":"2577330684","title":"富士莱(301258.SZ)发布前三季度业绩，归母净利润7339.66万元，增长430.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577330684","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577330684?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:27","pubTimestamp":1761218850,"startTime":"0","endTime":"0","summary":"智通财经APP讯，富士莱(301258.SZ)发布2025年三季度报告，该公司前三季度营业收入为3.23亿元，同比增长3.23%。归属于上市公司股东的净利润为7339.66万元，同比增长430.16%。归属于上市公司股东的扣除非经常性损益的净利润为251.19万元，同比增长119.80%。基本每股收益为0.8099元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"富士莱(301258.SZ)发布前三季度业绩，归母净利润7339.66万元，增长430.16%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301258"],"gpt_icon":0},{"id":"2577259356","title":"富士莱：截至2025年10月20日股东总户数为11,018户","url":"https://stock-news.laohu8.com/highlight/detail?id=2577259356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577259356?lang=zh_cn&edition=full","pubTime":"2025-10-22 16:12","pubTimestamp":1761120734,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)10月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止至2025年10月20日收盘公司股东人数为多少，谢谢！富士莱回复：尊敬的投资者，您好！截至2025年10月20日股东总户数为11,018户，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200024675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0},{"id":"2575214082","title":"富士莱（301258）披露首次回购公司股份的公告，10月14日股价上涨1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575214082","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575214082?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:56","pubTimestamp":1760453777,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘，富士莱报收于33.8元，较前一交易日上涨1.44%，最新总市值为30.98亿元。该股当日开盘33.77元，最高34.27元，最低33.68元，成交额达4655.95万元，换手率为1.54%。近日，富士莱发布《关于首次回购公司股份的公告》。公司实施回购符合相关法规及回购方案规定。后续将根据市场情况继续实施回购，并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766515685298,"stockEarnings":[{"period":"1week","weight":0.066},{"period":"1month","weight":0.0182},{"period":"3month","weight":-0.024},{"period":"6month","weight":0.128},{"period":"1year","weight":0.3333},{"period":"ytd","weight":0.3999}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1367},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.1695}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州富士莱医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9810人(较上一季度减少0.01%)","perCapita":"9079股","listingDate":"2022-03-29","address":"江苏省苏州市常熟市新材料产业园海旺路16号","registeredCapital":"9167万元","survey":"　　苏州富士莱医药股份有限公司的主营业务是医药中间体、原料药及保健品原料的研发、生产和销售。公司的主要产品是硫辛酸系列、磷脂酰胆碱系列、肌肽系列、艾瑞昔布。公司多年来连续被认定为“高新技术企业”。","listedPrice":48.3},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供富士莱(301258)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"富士莱,301258,富士莱股票,富士莱股票老虎,富士莱股票老虎国际,富士莱行情,富士莱股票行情,富士莱股价,富士莱股市,富士莱股票价格,富士莱股票交易,富士莱股票购买,富士莱股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"富士莱(301258)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供富士莱(301258)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}